TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32286005

Group type: EXPERIMENTAL
Intervention: Patient-targeted feedback intervention after depression screening using the Patient Health Questionnaire (PHQ-9)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Workshops conducted with patients
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Public and Patient Engagement Evaluation Tools (PPEET)
Number of subjects: 12
Study: 35897363

Group type: EXPERIMENTAL
Intervention: 38% Silver Diamine Fluoride (SDF)
Number of subjects: 290

Group type: COMPARATOR
Intervention: 5% Sodium Fluoride (NaF) varnish
Number of subjects: 290
Study: 33977744

Group type: EXPERIMENTAL
Intervention: Above-knee lateral approach (Group L)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Anterior approach (Group A)
Number of subjects: 53
Study: 32419378

Group type: EXPERIMENTAL
Intervention: Healthy diet (low in carbohydrates, rich in omega-3 fatty acids, vitamins C and D, antioxidants, and fiber)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Standard diet (high in processed carbohydrates)
Number of subjects: 14
Study: 34535300

Group type: EXPERIMENTAL
Intervention: Fixed dose of 1000 IU of 4F-PCC
Number of subjects: 199

Group type: COMPARATOR
Intervention: Variable dosing of 4F-PCC
Number of subjects: 199
Study: 33625393

Group type: EXPERIMENTAL
Intervention: 3-unit fiber-reinforced RBFDPs
Number of subjects: 50

Group type: COMPARATOR
Intervention: 3-unit metal-ceramic RBFDPs
Number of subjects: 50

Group type: COMPARATOR
Intervention: 2-unit cantilevered metal-ceramic RBFDPs
Number of subjects: 50
Study: 32902644

Group type: EXPERIMENTAL
Intervention: Exercise Training (ET) for 4 months
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Exercise Training (ET) with omega-3 supplementation (Calanus oil) for 4 months
Number of subjects: 55

Group type: COMPARATOR
Intervention: Physically active/fit (trained)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Sedentary/less physically fit (untrained)
Number of subjects: 55
Study: 34023889

Group type: EXPERIMENTAL
Intervention: Genetic predisposition to AF
Number of subjects: 588190

Group type: EXPERIMENTAL
Intervention: Allele score for AF
Number of subjects: 588190

Group type: COMPARATOR
Intervention: Genetically predicted eGFR
Number of subjects: 588190

Group type: COMPARATOR
Intervention: Allele score for eGFR
Number of subjects: 588190
Study: 33398869

Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral block (TPVB) performed unilaterally at T6 before surgery
Number of subjects: 78

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 78
Study: 36078048

Group type: EXPERIMENTAL
Intervention: Clonidine 150 μg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 33878338

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg
Number of subjects: 270

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study: 36113085

Group type: EXPERIMENTAL
Intervention: Avatrombopag
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34537006

Group type: EXPERIMENTAL
Intervention: Erenumab 70 mg
Number of subjects: 261

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 261
Study: 36092193

Group type: EXPERIMENTAL
Intervention: Bacillus clausii (Strains O/C, N/R, SIN and T) suspension available as Enterogermina® at the dose of 2 billion spores/5 ml twice daily for 8 weeks along with conventional treatment.
Number of subjects: 114

Group type: COMPARATOR
Intervention: Conventional treatment only.
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Bacillus clausii supplementation along with conventional treatment.
Number of subjects: 114
Study: 34233966

Group type: EXPERIMENTAL
Intervention: Probiotic and egg oral immunotherapy (OIT) administered once daily for 18 months
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo administered once daily for 18 months
Number of subjects: 80
Study: 35525625

Group type: COMPARATOR
Intervention: Control group (n=14) - cast-free digital workflow
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Test group (n=14) - partially digital workflow
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28
Study: 33083816

Group type: EXPERIMENTAL
Intervention: Spot urine samples
Number of subjects: 24

Group type: COMPARATOR
Intervention: 24-hour urine samples
Number of subjects: 24
Study: 35726287

Group type: EXPERIMENTAL
Intervention: Artificial intelligence FCM algorithm for MRI diagnosis
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Comprehensive nursing intervention
Number of subjects: 116

Group type: COMPARATOR
Intervention: Routine nursing (Control)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Postoperative adverse reactions (Control)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Postoperative adverse reactions (Experimental)
Number of subjects: 116
Study: 33113161

Group type: EXPERIMENTAL
Intervention: Hyoscine‐N‐butylbromide 20 mg (1 mL)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Sterile water (1 mL)
Number of subjects: 126
Study: 616707197

Group type: EXPERIMENTAL
Intervention: Computer-assisted safer sex intervention delivered through three individual sessions tailored to participants' needs, incorporating elements of motivational interviewing and cognitive-behavioral therapy.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 0
Study: 33231281

Group type: EXPERIMENTAL
Intervention: Ketorolac group (50 mg bupivacaine + 30 mg ketorolac)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Bupivacaine group (50 mg bupivacaine)
Number of subjects: 54
Study: 34537835

Group type: EXPERIMENTAL
Intervention: CoronaVac vaccine
Number of subjects: 434

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 434
Study: 32502775

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided lumbar plexus block (LPB)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Suprainguinal fascia iliaca block (SIFIB)
Number of subjects: 60
Study: 35470300

Group type: EXPERIMENTAL
Intervention: Aggressive Hydration (vHR) with lactated Ringer's solution (3 mL/kg/h during procedure, 20 ml/kg bolus immediately afterward, then 3 mL/kg/h for another 8 hours)
Number of subjects: 352

Group type: COMPARATOR
Intervention: High-dose Rectal Indomethacin (100 mg suppository immediately post-ERCP)
Number of subjects: 352
Study: 34258265

Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CRS+HIPEC)
Number of subjects: 100
Study: 614031389

Group type: EXPERIMENTAL
Intervention: TPB‐based intervention program delivered during 6 weeks postpartum
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: TPB‐based intervention program
Number of subjects: 285

Group type: COMPARATOR
Intervention: Standard obstetric care (Control)
Number of subjects: 285
Study: 35736027

Group type: EXPERIMENTAL
Intervention: Lasmiditan
Number of subjects: 846

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 846
Study: 32534083

Group type: EXPERIMENTAL
Intervention: Dermoscopic reticular pattern
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Dermoscopic globular pattern
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Dermoscopic complex pattern
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Dermoscopic homogenous pattern
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Dermoscopic clinical regression model
Number of subjects: 112
Study: 32987359

Group type: EXPERIMENTAL
Intervention: Baseline Montreal Cognitive Assessment (MoCA) memory performance
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Baseline MoCA memory
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Increasing subjective cognitive complaints in Neuro‐QoL‐EF
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Baseline depression and anticholinergic use
Number of subjects: 324
Study: 36325678

Group type: EXPERIMENTAL
Intervention: Onabotulinumtoxin-A (treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.9% sodium-chloride solution (placebo)
Number of subjects: 0
Study: 33421863

Group type: EXPERIMENTAL
Intervention: Smartphone-based monitoring and treatment system
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 120
Study: 34302282

Group type: EXPERIMENTAL
Intervention: Community-based sexual and reproductive health services (HTS)
Number of subjects: 5757

Group type: EXPERIMENTAL
Intervention: Community-based hubs for HIV testing
Number of subjects: 5757
Study: 34357493

Group type: EXPERIMENTAL
Intervention: Neoadjuvant letrozole and exemestane given sequentially for at least 4 months
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Type II MRI pattern (fragmentation)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Type IV MRI pattern
Number of subjects: 50
Study: 35159340

Group type: EXPERIMENTAL
Intervention: Intensive Strength Training (IST: 3×10 reps at 80% 1RM)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Strength Endurance Training (SET: 2×30 reps at 40% 1RM)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (CON: 3×30 sec stretching)
Number of subjects: 14
Study: 34403280

Group type: EXPERIMENTAL
Intervention: Pretrial cue to target location with three-voice masker
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Location-unknown condition with three-voice masker
Number of subjects: 0

Group type: COMPARATOR
Intervention: One-voice masker
Number of subjects: 0

Group type: COMPARATOR
Intervention: Noise-burst masker
Number of subjects: 0
Study: 33768245

Group type: EXPERIMENTAL
Intervention: Levcromakalim (0.05 mg/min infusion)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (isotonic saline)
Number of subjects: 17
Study: 33215889

Group type: EXPERIMENTAL
Intervention: Low Amplitude Seizure Therapy (LAP-ST)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Standard Right Unilateral Electroconvulsive Therapy (RUL ECT)
Number of subjects: 11
Study: 35640205

Group type: EXPERIMENTAL
Intervention: Intervention practices with patient enrolment, longer appointments, and early post-hospital follow-up.
Number of subjects: 774

Group type: COMPARATOR
Intervention: Control practices without the intervention.
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: Both intervention and control groups.
Number of subjects: 774
Study: 34825102

Group type: EXPERIMENTAL
Intervention: Community advertising (newspapers)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Social media (Craigslist)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Social media (Facebook and LinkedIn)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General recruitment efforts
Number of subjects: 0
Study: 34850952

Group type: EXPERIMENTAL
Intervention: DMARD treatment (increased from 17% in 1993-1997 to 52% in 2015-2019)
Number of subjects: 1132

Group type: EXPERIMENTAL
Intervention: DMARD treatment
Number of subjects: 1132
Study: 33769862

Group type: EXPERIMENTAL
Intervention: Ribociclib (RIB)
Number of subjects: 1160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1160
Study: 32659784

Group type: EXPERIMENTAL
Intervention: Dynamic treatment regimens (DTRs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Joint modeling approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple comparisons with the best method
Number of subjects: 0
Study: 33837509

Group type: EXPERIMENTAL
Intervention: ePRO (electronic patient-reported outcomes)
Number of subjects: 347

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: ePRO
Number of subjects: 347
Study: 33295870

Group type: EXPERIMENTAL
Intervention: L-DOPA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32324852

Group type: EXPERIMENTAL
Intervention: Guideline-directed medical therapy (GDMT) in CABG arm
Number of subjects: 1212

Group type: EXPERIMENTAL
Intervention: Guideline-directed medical therapy (GDMT) in medical therapy arm
Number of subjects: 1212

Group type: COMPARATOR
Intervention: Medical therapy alone (control group)
Number of subjects: 1212
Study: 34736885

Group type: EXPERIMENTAL
Intervention: Adhesive elastic tape applied after cast application
Number of subjects: 220

Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Adhesive elastic tape
Number of subjects: 220
Study: 33025104

Group type: EXPERIMENTAL
Intervention: Non-Doppler hemorrhoidal artery ligation and hemorrhoidopexy under pudendal nerve block
Number of subjects: 60

Group type: COMPARATOR
Intervention: Doppler guided hemorrhoidal artery ligation and hemorrhoidopexy under spinal anesthesia
Number of subjects: 60
Study: 32271261

Group type: EXPERIMENTAL
Intervention: semaglutide 2 mg/1.5 ml (1.34 mg/ml) prefilled pen for subcutaneous injection
Number of subjects: 140

Group type: COMPARATOR
Intervention: placebo 1.5 ml, pen-injector for subcutaneous injection
Number of subjects: 140
Study: 36348660

Group type: EXPERIMENTAL
Intervention: Sodium lowering intervention (target <100mmol/day) through specific counseling (sodium use in foods, fresh over processed foods, sodium content of foods and eating outside of home)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care only (healthy eating)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium lowering intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium lowering intervention (target <100mmol/day) through specific counseling (sodium use in foods, fresh over processed foods, sodium content of foods and eating outside of home)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care only (healthy eating)
Number of subjects: 0
Study: 32217051

Group type: EXPERIMENTAL
Intervention: 0.1 grading increment
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: 0.5 grading increment
Number of subjects: 188

Group type: COMPARATOR
Intervention: 1.0 grading increment
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: 0.5 grading increments
Number of subjects: 188
Study: 36057645

Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Nasal intermittent positive pressure ventilation (NIPPV)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Non-invasive neurally adjusted ventilatory assist (NIV-NAVA)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (extubation failure)
Number of subjects: 23
Study: 33498834

Group type: EXPERIMENTAL
Intervention: Text messaging and mailed nicotine replacement medication
Number of subjects: 22
Study: 32178704

Group type: EXPERIMENTAL
Intervention: Tuina
Number of subjects: 160

Group type: COMPARATOR
Intervention: Health care education
Number of subjects: 160
Study: 33352008

Group type: EXPERIMENTAL
Intervention: PF-06823859 (SAD) 30, 100, 300, 900, or 2000 mg
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: PF-06823859 (MAD) 100 or 300 mg
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: PF-06823859 (MAD) 600 mg
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: PF-06823859 (SAD and MAD)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (SAD and MAD)
Number of subjects: 62
Study: 36120797

Group type: EXPERIMENTAL
Intervention: Trunk stabilization exercises using laser pointer visual feedback
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Traditional stroke rehabilitation program and trunk stabilization exercises using laser pointer visual feedback
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional stroke rehabilitation program and trunk stabilization exercises without visual feedback
Number of subjects: 30
Study: 34427687

Group type: EXPERIMENTAL
Intervention: Positive psychology intervention for diabetes distress; details on dosage and duration not available.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Remote protocol adaptation due to COVID-19; details on dosage and duration not available.
Number of subjects: 0
Study: 36300304

Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg every 2 weeks for up to 120 days after radical surgery
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg every 2 weeks for up to 120 days after radical surgery (in patients with PD-L1 expression level of 1% or more)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo (in patients with PD-L1 expression level of 1% or more)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Nivolumab and Placebo
Number of subjects: 49
Study: 32711920

Group type: EXPERIMENTAL
Intervention: Helical tomotherapy IMRT (HT-IMRT)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Forward field-in-field breast IMRT (FiF-IMRT)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Both FiF-IMRT and HT-IMRT
Number of subjects: 177

Group type: COMPARATOR
Intervention: FiF-IMRT
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: HT-IMRT
Number of subjects: 177
Study: 32297396

Group type: EXPERIMENTAL
Intervention: Group intervention combining self-care and self-hypnosis
Number of subjects: 95

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 95
Study: 35394514

Group type: EXPERIMENTAL
Intervention: Plasma donation every 6 weeks for 12 months
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Blood donation every 12 weeks for 12 months
Number of subjects: 285

Group type: COMPARATOR
Intervention: Observation only
Number of subjects: 285
Study: 32926286

Group type: EXPERIMENTAL
Intervention: 15N-labeled urea (5% 15N atom excess) at 60 mg N kg-1 soil with 50 mg Ni kg-1 soil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acetic acid addition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher rates of Ni addition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (0 mg N and 0 mg Ni)
Number of subjects: 0
Study: 32951698

Group type: EXPERIMENTAL
Intervention: Verum acupuncture (traditional penetrating acupuncture)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Sham acupuncture (non-penetrating sham-needle)
Number of subjects: 200
Study: 34214683

Group type: EXPERIMENTAL
Intervention: AC niosome gel
Number of subjects: 60

Group type: COMPARATOR
Intervention: AC gel
Number of subjects: 60

Group type: COMPARATOR
Intervention: Triamcinolone gel
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 60
Study: 32340219

Group type: EXPERIMENTAL
Intervention: Tailored health brochures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-tailored health brochures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (no print information materials)
Number of subjects: 0
Study: 33991432

Group type: EXPERIMENTAL
Intervention: Behavioral therapy (BT) - 5 sessions including diaphragmatic breathing exercises
Number of subjects: 42

Group type: COMPARATOR
Intervention: Follow-up without intervention (Control)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Behavioral therapy (BT) - 5 sessions
Number of subjects: 42
Study: 34132018

Group type: EXPERIMENTAL
Intervention: Liraglutide (≤1.8 mg/day)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 303
Study: 36077737

Group type: EXPERIMENTAL
Intervention: Mediterranean Diet (MedDiet) intervention
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Mediterranean Diet (MedDiet) intervention for those with baseline MedDiet score <5 (n = 21)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 33
Study: 33399377

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided bilateral mid-axillary TAP block with 20 ml of bupivacaine 0.25% (Group T)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 0.9% saline (Group C)
Number of subjects: 50
Study: 34483247

Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone (8 mg/24 h) administered via Microwick device
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (contralateral ear without treatment)
Number of subjects: 34
Study: 33704806

Group type: EXPERIMENTAL
Intervention: Selgantolimod (1.5 mg for 2 weeks or 3 mg for 2 or 4 weeks)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 33302352

Group type: EXPERIMENTAL
Intervention: Exercise and nutrition intervention (supplement of branched-chain amino acids, calcium and vitamin D3) for 12 weeks in the sarcopenic group.
Number of subjects: 72

Group type: COMPARATOR
Intervention: Non-sarcopenic controls (no intervention).
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Sarcopenic participants (no intervention).
Number of subjects: 72
Study: 36049557

Group type: EXPERIMENTAL
Intervention: Everolimus (days 1-3: 7.5 mg daily; days 4-5: 5.0 mg daily)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 34898152

Group type: EXPERIMENTAL
Intervention: 50% Glycolic Acid peel plus Novel Protective Complex (NPC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 50% Glycolic Acid peel (Control)
Number of subjects: 20
Study: 34533059

Group type: EXPERIMENTAL
Intervention: Highest tertile of BPV (SD 16.3±3.6 mm Hg)
Number of subjects: 8379

Group type: COMPARATOR
Intervention: Lowest tertile of BPV (SD 6.3±1.6 mm Hg)
Number of subjects: 8379

Group type: COMPARATOR
Intervention: Middle tertile of BPV (SD 10.3±1.1 mm Hg)
Number of subjects: 8379
Study: 32293725

Group type: EXPERIMENTAL
Intervention: Etoposide and cisplatin (EP)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Irinotecan and cisplatin (IP)
Number of subjects: 66
Study: 36058913

Group type: EXPERIMENTAL
Intervention: Change Club (CC) intervention
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control communities
Number of subjects: 10
Study: 34411738

Group type: EXPERIMENTAL
Intervention: Autofluorescence visualization using VELscope before ablative surgical resection
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Immunohistochemical staining of Ki‐67, E‐cadherin, and Vimentin
Number of subjects: 30
Study: 34922258

Group type: COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High flow nasal cannula (HFNC) at 20 L/min
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High flow nasal cannula (HFNC) at 30 L/min
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High flow nasal cannula (HFNC) at 40 L/min
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High flow nasal cannula (HFNC)
Number of subjects: 40
Study: 32602616

Group type: EXPERIMENTAL
Intervention: Budesonide (tapering doses from 9 to 3 mg for 12 weeks)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 20
Study: 35675469

Group type: EXPERIMENTAL
Intervention: Omecamtiv mecarbil
Number of subjects: 8232

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8232
Study: 33548659

Group type: EXPERIMENTAL
Intervention: Friction RandomPOD device with serum lubricated polyethylene/CoCr tests
Number of subjects: 0